ISRCTN14881129
Completed
未知
A randomized, single-blind, placebo-controlled study assessing the acute effects of hibiscus sabdariffa on cardiometabolic markers and cognitive function in metabolically challenged individuals
niversity of Leeds0 sites20 target enrollmentJune 20, 2024
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Reduction of blood pressure
- Sponsor
- niversity of Leeds
- Enrollment
- 20
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Age 18\-56
- •2\. BMI more than 27kg/m2 but less than35kg/m2
- •3\. Male and female, local to the Leeds area
- •4\. Presence of high blood pressure
- •5\. Sufficient knowledge and understanding of the English language (preferably first language)
Exclusion Criteria
- •1\. For women – pregnancy, lactation, perimenopause/menopause
- •2\. Food allergy or intolerance to any of the study foods
- •3\. Medical conditions – clinical depression, thyroid diseases, hypertension, type 1 or type 2 diabetes, or blood diseases
- •4\. Using any medication for hypertension or cholesterol\-lowering sterols
- •5\. Recent blood donation (\<3 months)
- •6\. Participation in simultaneous studies
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Evaluation of Efficacy and Safety of Sarilumab in Patients with GCAEUCTR2017-002988-18-SESanofi-Aventis Recherche & Développement508
Active, not recruiting
Not Applicable
A clinical study to evaluate the efficacy and tolerability of a novel herbal composition to relieve constipation and to improve bowel clearanceCTRI/2022/09/046036Bohan and Co
Active, not recruiting
Phase 1
Evaluation of the Efficacy and Safety of Sarilumab in Patients with Polymyalgia RheumaticaEUCTR2017-002989-42-DKSanofi-Aventis Recherche & Développement500
Active, not recruiting
Phase 1
Evaluation of Efficacy and Safety of Sarilumab in Patients with GCAEUCTR2017-002988-18-DKSanofi-Aventis Recherche & Développement508
Active, not recruiting
Not Applicable
A randomized, double-blind, placebo-controlled study to evaluate the safety of 12 weeks of dosing with GW856553 and its effects on inflammatory markers, infarct size, and cardiac function in subjects with myocardial infarction without STsegmentelevation - SOLSTICESubjects with myocardial infarction without ST-segment elevationMedDRA version: 9.1Level: LLTClassification code 10064347Term: Non ST segment elevation myocardial infarctionEUCTR2009-010615-32-NLGlaxoSmithKline R&D Ltd400